Dr. Shrikant Mishra
Professor,Head (Technology & Translational Research)
Ph.D. Virginia Tech, Blacksburg, U.S.A
M.Sc.St. Stephen’s College, Delhi University


Email: [email protected]

Post-Doctoral Training

  • Virginia Tech, Blacksburg, U.S.A
  • University Of Maryland Cancer Center, Baltimore, Maryland, U.S.A
  • Mayo Clinic , Rochestor, Minnesota, U.S.A

Research Interest

My current interest is in development of commercial platforms using translational technologies. We have developed four technologies for scale up in last one year

Awards/Honors

  • Recipient of Biotechnology Ignition Grant (BIG) for multi-drug resistance (2014-current)
  • Recipient of MSME Award for development of culture media for CHO DG44 cells ( 2013-Current)
  • Jury, Biotech Projects, Confederation Of Indian Industries (C.I.I)(2013-current)
  • Advisor, Technology Commercialization Facilitation Agency (T.C.F.A) (2013-current)
  • Member, Indian Science Congress (2013-present)

Selected Publications

Full List
  1. US20090035815: Synthetic Gene For Enhanced Expression In E. Coli
  2. WO2009019715: Novel Orthogonal Process For Purification Of Recombinant Human Parathyroid Hormone (Rhpth) (1 34)
  3. WO2008136014: Cloning And Expression Of Enterokinase And Its Process For Production
  4. US20070249806: Solid Phase Fmoc Chemistry Process To Prepare Peptides
  5. KR1020070083387: A Novel Process For Purification Of Human Growth Harmone

Projects under Development at TTRL:

  1. A topical gel for rheumatoid arthritis(RA) and flow ELISA for RA diagnostics.
    This project has intramural funding, and is at Tech Pack stage. Analytical optimization has been completed.
  2. An anti-fungal active. This project has completed POC stage and is at optimization.
  3. Recombinant Enabling MDR Platform—Funded by DBT---USD80,000/--2014—present.
    This project involves cloning of phage lysins as chimera with human IgG Fc and development of a product by process for XDR TB. This project is at proof of concept stage and aims to make a nasay spray for zero burden XDR TB.
  4. Making Of CHO DG44 Culture media ---Funded by MSME---USD 8,000 /--2014---present and seeking a BIG grant of USD 80,000/.
    The project involve making of a variant of DMEM / F12 medium using Mahua extract for recombinant production using CHO DG44 cells. This project is at R&D stage.
  5. Recombinant chimeric drugs : for  immune suppression during sepsis. Submitted for funding.
    This project involves cloning of GPCRs of C3a and C5a receptors as Fc-C3a and Fc-C5a for reduction of inflammatory peptides implicated in sepsis. This project is seeking funding.
  6. Societal Nutritional Project For Tribal Women of Koraput District, Orissa : Funded for $80,000/.
 

Patents:

  • Patent Application (2014) : Two components skin sanitizing/moisturizing system
  • US20090035815: Synthetic Gene For Enhanced Expression In E. Coli
  • WO2009019715: Novel Orthogonal Process For Purification Of Recombinant Human Parathyroid Hormone (Rhpth) (1 34) WO2009005973:Synthetic Gene For Enhanced Expression In E.Coli
  • WO2008136014: Cloning And Expression Of Enterokinase And Its Process For Production
  • US20070249806: Solid Phase Fmoc Chemistry Process To Prepare Peptides
  • KR1020070083387: A Novel Process For Purification Of Human Growth Harmone
  • CA2641372: Affinity Polypeptide For Purification Of Recombinant Proteins KR20070094902:Low Cell Density Fermentation Process For The Production Of Heterologous Recombinant Proteins In Microorganisms
  • KR20070083387: A Novel Process For Purification Of Human Growth Hormone
  • EP1758933: Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
  • WO2006051554: A Novel Process For Purification Of Human Growth Harmone
  • CA2589716: Low Cell Density Fermentation Process For The Production Of Heterologous Recombinant Proteins In Microorganisms
  • CA2565209: A Novel Process For Purification Of Human Growth Harmone
  • CA25 AU2004324756: A Novel Process For Purification Of Human Growth Harmone
  • AU2004320986: Chimeric Human Growth Hormone Derived From The Placenta And Pituitary Isoform And Processes For Obtaining Said Chimera
  • 60007: Process For The Preparation Of Peptides
  • AU2004320599: Process For The Preparation Of Peptides
  • WO2006001027: Chimeric Human Growth Hormone Derived from the Placenta and Pituitary Isoform and Process for obtaining the same.
  • WO 2006/05/554 : A Novel Process For Purification of Human Growth Hormone
  • WO 2006067793 : Low Cell Density Fermentation Process for the production of Hetrologous Recombinant protein in Microorganisms.
  • WO2005121164 : A process for the preparation of peptides
  • WO2007096899: Affinity Polypeptide for Purification of recombinant protein
  • US2007249806 : Solid Phase FMOC Process to Prepare Peptides
  • PCT/IN/2007/000277 : Cloning and expression of enterokinase and it’s process for production
  • 247 / MUM/2007 : Synthetic gene for enhanced expression in E. Coli
  • 1543 / MUM/2007/ : Novel orthogonal process for the purification of recombinant human parathyroid hormone rhPTH (1-34)
  • 1776/MUM/2007: An improved process for FMOC synthesis of Ecosapeptide

Publications:

  • Simplifying diagnostic procedures in pancreatic cancers , Review (2014,under submission)
  • Association of inhibition of cell growth by O-phospho-L-Tyr with decreased tyrosine phosphorylation.. Cancer Letters. 1996, 102(1-2): 65-71
  • A microtiter assay for Cu/Zn and Mn- superoxide dismutase. Ind. J. Biochem. Biophys. 1996 (vol 33, 1996, pp319-322)
  • A spin decay assay for tumor necrosis factor cytoxicity. Ind. J. Biochem. Biophys. 32, 254-260, 1995
  • Regulation of the suspected tumor suppressor gene product CLP in human breast epithelial cells. J. Cell. Biochem. 18 (Supp):171
  • Regulation of expression and search for specific tumor suppressor gene product. Mini paper, 3rd European Symp. On Ca Binding Proteins. Zurich, Switzerland, march 6-9, 1994
  • Modulation of the cytotoxicity activity of tumor necrosis factor by protein tyrosine kinase and protesin tyrosine phosphatise inhibitors. Lymphokine & cytokine Research. 13(2), 77-83, 1994.
  • Interferon –gamma induced reduction in erb B-2 Tyrosyl Phosphorylation in human ovarian carcinoma cells. Int. J. Cancer, 58, 538-542, 1994.
  • A case of recurrent eclampsia.Post grad. Med. J. 1994, 70(828):769.
  • A microtiter enzyme linked immunosorbent assay for protein tyrosine phosphatise. Biochem. Biophys. Acta. 1157: 93-101, 1993.
  • Exogenous phosphotyrosine modulates epidermal growth factor receptor tyrosine phosphorylation. Carcinogenisis 14 : 273, 1993
  • O-Phospho-L-Tyr inhibits cell growth by activating protein tyrosine phosphatises. Cancer Research. 53 : 557-563, 1993.
  • Role of intracellular Ca++ in the epidermal growth factor induced inhibition of protein tyrosine phosptahaase activity in a breast cancer cell line. Biochem. Biophys. Res. Commun., 191: 1065-1072, 1993.
  • Interferon enhancement of tyrosine phosphorylation of epidermal growth factor receptors in human breast carcinoma cells. Anticancer Res. 13, 613-618, 1993.
  • O-phospho-L-tyr inhibits cellular growth by activating protein tyrosine phosphatises. Keystone Symposia on Signalling, Keystone , CO, 1993
  • Preclampsia J. Perinatol, 1993, 13(5): 417-8
  • Regulation of suspected tumor suppressor gene product CLP in human breast epithelial cells. Keystone Symposia on Tumor Suppressor Genes. Taos, NM, 1994
  • O-phospho-L-tyr inhibits cellular growth by activating protein tyrosine phosphatises.J. Cell. Biochem. Suppl. 17A, BZ 624, 1993
  • Regulation of tyrosine phosphorylation of epidermal growth factor in breast cancer cell lines by gamma-interferon.  Proceedings of 83rd Annual Meeting of the American Association for Cancer Research 33: 3(14), 1992.
  • Microtiter enzyme linked immunosorbent assay for protein tyrosine phosphatise. World Congress of Cell and tissue Culture Washington DC, 1992.
  • Mechanism of TNF-alpha cytotoxicity in a retrovial transformation model. Ph.D Thesis ( 1991)
  • Tumor necrosis factor modulates tyrosine phosphorylation of A-MuLV specific cell surface antigen. 7251, FASEB J. 5(6): 1619, 1991.
  • EPR observation of TEMPO quenching in monitoring TNF alpha cytotoxicity in L929 cells. Rocky Mountain Conference on Analytical Chemistry, 1991.
  • Role of free radicals during reperfusion injury in isolated rat lungs. American Physiological Society Conference Proceedings, 1990.
  • Reversal of superoxide dismutase reaction as detected by EPR spin trapping techniques. Conference proceedings of Federation of American Society of Experimental Biology. 2115, 1990.
  • Regulation of manganese superoxide dismutase in endothelial cells. J. Cell. Biol. 107: 217a, 1989.
  • Mechanism of microwave induced membrane damage in human erythrocytes. J. cell. Biol. 107, 188a, 1989.
  • Broken symmetry of biomolecules. Biophysical. J. , 151; 96a, 1987.